RedHill Biopharma Ltd. (RDHL) News
Follow RedHill Biopharma Ltd. (RDHL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
RedHill combination awarded $2.9 million NCI grant
A $2.9 million NCI grant was awarded for clinical development of RedHill’s opaganib and CAR T-cell combination in ultra-high-risk multiple myeloma.
EQUITY | Oct 19, 2026, 12:01 PM UTC
M
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher
The market saw deepening losses this week, with small-cap stocks underperforming and yields trending upward as investors braced for the upcoming earnings season.
MACRO | Oct 01, 2026, 07:13 PM UTC
M
RedHill buys commercialization rights for Ferring GI drugs
RedHill says its acquisition from Ferring of commercialization rights to Rebyota® and Clenpiq®, together with the previously announced Talicia® divestiture, completes a strategic divestiture plan.
MNA | Sep 01, 2026, 11:02 AM UTC
L
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17
EQUITY | Jul 01, 2026, 12:05 PM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
RDHL Raises $19.4M
RedHill Biopharma announces closing of up to $19.4 million private placement
EQUITY | Jun 22, 2026, 08:11 PM UTC